Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.

Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB.

Br J Cancer. 2012 Oct 9;107(8):1268-76. doi: 10.1038/bjc.2012.407. Epub 2012 Sep 20.

2.

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.

Kozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, De Castro Carpeño J, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB.

Br J Cancer. 2012 Oct 9;107(8):1277-85. doi: 10.1038/bjc.2012.406. Epub 2012 Sep 18.

3.

Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.

Nadella P, Shapiro C, Otterson GA, Hauger M, Erdal S, Kraut E, Clinton S, Shah M, Stanek M, Monk P, Villalona-Calero MA.

J Clin Oncol. 2002 Jun 1;20(11):2616-23.

PMID:
12039922
4.

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.

Sharma S, Abhyankar V, Burgess RE, Infante J, Trowbridge RC, Tarazi J, Kim S, Tortorici M, Chen Y, Robles RL.

Ann Oncol. 2010 Feb;21(2):297-304. doi: 10.1093/annonc/mdp489. Epub 2009 Nov 25.

PMID:
19940012
5.

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.

Michael M, Vlahovic G, Khamly K, Pierce KJ, Guo F, Olszanski AJ.

Br J Cancer. 2010 Nov 9;103(10):1554-61. doi: 10.1038/sj.bjc.6605941. Epub 2010 Oct 19.

6.

Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.

Langenberg MH, Witteveen PO, Roodhart JM, Verheul HM, Mergui-Roelvink M, van der Sar J, Brendel E, Laferriere N, Schellens JH, Voest EE.

Clin Cancer Res. 2010 Apr 1;16(7):2187-97. doi: 10.1158/1078-0432.CCR-09-2436. Epub 2010 Mar 16.

7.

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.

Deenen MJ, Klümpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, Schellens JH, Wilmink JW.

Invest New Drugs. 2012 Aug;30(4):1557-65. doi: 10.1007/s10637-011-9723-4. Epub 2011 Aug 2.

8.

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.

Pronk LC, Vasey P, Sparreboom A, Reigner B, Planting AS, Gordon RJ, Osterwalder B, Verweij J, Twelves C.

Br J Cancer. 2000 Jul;83(1):22-9.

9.

Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.

Ramanathan RK, Ramalingam S, Egorin MJ, Belani CP, Potter DM, Fakih M, Jung LL, Strychor S, Jacobs SA, Friedland DM, Shin DM, Chatta GS, Tutchko S, Zamboni WC.

Cancer Chemother Pharmacol. 2005 Apr;55(4):354-60. Epub 2004 Oct 27.

PMID:
15723261
10.

Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.

Ernst T, Merx K, Gnad-Vogt U, Lukan N, Kripp M, Schultheis B, Hochhaus A, Hofheinz RD.

Br J Cancer. 2007 Dec 3;97(11):1475-9. Epub 2007 Nov 13.

11.

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study.

Isakoff SJ, Wang D, Campone M, Calles A, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Calvo E.

Br J Cancer. 2014 Nov 25;111(11):2058-66. doi: 10.1038/bjc.2014.508. Epub 2014 Oct 7.

12.

A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.

Han JY, Lee DH, Kim HY, Hong EK, Yoon SM, Chun JH, Lee HG, Lee SY, Shin EH, Lee JS.

Cancer. 2003 Nov 1;98(9):1918-24.

13.

Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer.

Bondarenko IM, Ingrosso A, Bycott P, Kim S, Cebotaru CL.

BMC Cancer. 2015 May 1;15:339. doi: 10.1186/s12885-015-1350-6.

14.

Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer.

Spano JP, Moore MJ, Pithavala YK, Ricart AD, Kim S, Rixe O.

Invest New Drugs. 2012 Aug;30(4):1531-9. doi: 10.1007/s10637-011-9697-2. Epub 2011 Jun 14.

PMID:
21670972
15.

Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours.

Hoh CK, Burris HA 3rd, Bendell JC, Tarazi J, Rosbrook B, Kim S, Infante JR, Reid TR.

Br J Cancer. 2014 Feb 18;110(4):875-81. doi: 10.1038/bjc.2013.806. Epub 2014 Jan 14.

16.
17.

Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.

Blum JL, Dees EC, Vukelja SJ, Amare M, Gill DP, McMahon RT, Ilegbodu D, Asmar L, O'Shaughnessy JA.

Clin Breast Cancer. 2007 Feb;7(6):465-70.

PMID:
17386123
18.

The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.

Algazi AP, Cha E, Ortiz-Urda SM, McCalmont T, Bastian BC, Hwang J, Pampaloni MH, Behr S, Chong K, Cortez B, Quiroz A, Coakley F, Liu S, Daud AI.

Br J Cancer. 2015 Apr 14;112(8):1326-31. doi: 10.1038/bjc.2014.541. Epub 2015 Mar 31.

19.

Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial.

Ioka T, Okusaka T, Ohkawa S, Boku N, Sawaki A, Fujii Y, Kamei Y, Takahashi S, Namazu K, Umeyama Y, Bycott P, Furuse J.

Jpn J Clin Oncol. 2015 May;45(5):439-48. doi: 10.1093/jjco/hyv011. Epub 2015 Feb 3.

20.

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.

Sweeney CJ, Chiorean EG, Verschraegen CF, Lee FC, Jones S, Royce M, Tye L, Liau KF, Bello A, Chao R, Burris HA.

J Clin Oncol. 2010 Oct 10;28(29):4513-20. doi: 10.1200/JCO.2009.26.9696. Epub 2010 Sep 13.

Supplemental Content

Support Center